Forchheim, Germany Clinical Trials

A listing of Forchheim, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 130 clinical trials
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who roll-over into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. …

metastasis
mk-3475
pembrolizumab
major surgery
Universit tsklinikum Erlangen ( Site 2408)
 (8.7 away) Contact site
  • 522 views
  • 05 Aug, 2021
  • +267 other locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The primary …

immunostimulant
erbb2
cyclophosphamide
EGFR
epirubicin
Universitaetsklinikum Erlangen ( Site 1001)
 (8.7 away) Contact site
  • 188 views
  • 05 Aug, 2021
  • +286 other locations
A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease

This is a study in adults with Crohn's Disease who also have fistulas near the anus. The study has 2 parts. The first part is to find out more about what causes the fistulas. In this part of the study, tissue samples are taken from patients. The second part of …

biosimilar
adalimumab
certolizumab pegol
drainage
thiopurines
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 13 views
  • 21 Jul, 2021
  • +18 other locations
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis. At least 230 pediatric subjects (ages 6 through 17 years) will be randomized 2:1 to receive either apremilast or placebo for the first …

topical agents
systemic therapy
phototherapy
cc-10004
plaque psoriasis
Universitatsklinikum Erlangen
 (9.5 away) Contact site
  • 98 views
  • 04 Aug, 2021
  • +284 other locations
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).

neutrophil count
cell transplantation
platelet count
prednisone
corticosteroids
Universitaetsklinikum Erlangen - Medizinische Klinik 5
 (8.7 away) Contact site
  • 0 views
  • 04 Aug, 2021
  • +159 other locations
Randomized Trial of TAVI vs. SAVR in Patients With Severe Aortic Valve Stenosis at Intermediate Risk of Mortality

Randomized controlled, multi-center trial randomizing patients with symptomatic severe aortic stenosis at low to intermediate operative risk of mortality in a 1:1 fashion to transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) to test, whether TAVI is non-inferior to SAVR, as measured by all-cause mortality or stroke …

tavi
syncope
aortic valve stenosis
stroke
aortic valve replacement
Universit tsklinikum Erlangen
 (9.4 away) Contact site
  • 43 views
  • 26 Jan, 2021
  • +87 other locations
Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold

The FANTOM II trial is intended to assess safety and performance of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.

ischemia
stenosis
sirolimus
Universit tsklinikum Erlangen
 (8.7 away) Contact site
  • 21 views
  • 21 Jan, 2021
  • +19 other locations
Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML

The proposed trial will address two clinically important questions for younger patients with newly diagnosed acute myeloid leukemia (AML): the optimal dose of daunorubicin in induction therapy and the necessity of a second induction cycle in patients with a good response after the first induction. The primary endpoint is the …

neoadjuvant therapy
minimal residual disease
residual tumor
ejection fraction
daunorubicin
Universit tsklinikum Erlangen
 (9.4 away) Contact site
  • 33 views
  • 24 Jan, 2021
  • +40 other locations
Study of Intratumoral CV8102 in cMEL cSCC hnSCC and ACC

This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma. Patients will receive CV8102 as single agent or in combination with SoC anti-PD-1 therapy.

head and neck carcinoma
carcinoma
cancer
squamous cell carcinoma of the head and neck
measurable disease
Investigative Site
 (9.4 away) Contact site
  • 136 views
  • 09 Jul, 2021
  • +34 other locations
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The primary hypotheses are: Olaparib plus pembrolizumab prolongs progression-free survival (PFS) compared with chemotherapy plus pembrolizumab. Olaparib …

taxane
anthracyclines
measurable disease
triple negative breast cancer
carboplatin
Universitaetsklinikum Erlangen ( Site 1201)
 (8.7 away) Contact site
  • 241 views
  • 05 Aug, 2021
  • +133 other locations